Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate Cancer.
about
An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate CancerPerpetuating effects of androgen deficiency on insulin resistanceRisk of Alzheimer's Disease Among Senior Medicare Beneficiaries Treated With Androgen Deprivation Therapy for Prostate Cancer.Cardiovascular Complications of Androgen Deprivation Therapy for Prostate Cancer.Quality of sleep in patients receiving androgen deprivation therapy for prostate cancer.Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer.A meta-analysis of cardiovascular events in intermittent androgen-deprivation therapy versus continuous androgen-deprivation therapy for prostate cancer patients.Androgen deprivation therapy for prostate cancer and dementia risk: a systematic review and meta-analysis.Discrepancies on the association between androgen deprivation therapy for prostate cancer and subsequent dementia: meta-analysis and meta-regression.Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a prospective cohort study.Quality-of-life outcomes from the Prostate Adenocarcinoma: TransCutaneous Hormones (PATCH) trial evaluating luteinising hormone-releasing hormone agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancer.Androgen-deprivation therapy, dementia, and cognitive dysfunction in men with prostate cancer: How much smoke and how much fire?Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies.Management of Biochemical Recurrence after Primary Curative Treatment for Prostate Cancer: A Review.Clinical impact of 68 Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate-specific antigen after treatment with curative intent: preliminary anaRisks of Serious Toxicities from Intermittent versus Continuous Androgen Deprivation Therapy for Advanced Prostate Cancer: A Population Based Study.Intermittent androgen deprivation therapy in patients with prostate cancer: Connecting the dots.
P2860
Q26744431-F4FEC58C-AE2F-4B97-BB83-5965A024767CQ37478579-57557CC6-3632-4776-9956-6B39D9F0C464Q38608309-9680D878-CA59-49C0-B9CE-1F897757DBAFQ38707724-6E4778E8-A3E4-44C0-8A49-38E9F679C422Q38796656-6C445089-A150-4554-A92E-19084CBA205CQ38803264-29DEB1A0-96A7-4783-BEC1-4E554B32F9BBQ38946665-BAC44DB9-06B1-451A-BB90-3ABE9947A819Q39204570-1633BE0D-092E-449B-958C-E276968CEA8EQ42700699-CFC0291B-99D2-4BC3-A7C8-7E8B9CC9FB72Q46415794-5F57A264-D011-4530-B222-F8CB54AA5EAFQ47642158-30E0CE72-61CC-45AF-A225-9A104EA91E89Q47674478-4E154951-FA39-495F-A573-C3DC26A49BCFQ47774024-9B7FA8C9-1D20-407B-9757-0B2BFF039C02Q47826406-CE7FBF73-59B7-4D15-9320-154C091CEB59Q48898788-67C9AF60-413C-4AA2-9F64-F54D7A4BB01FQ49204760-D27A3513-B6B3-4914-B8AF-DD488B898D12Q54940363-DBCF139C-AAB8-464A-8B5F-3AF6F38E66FA
P2860
Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate Cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Adverse Health Events Followin ...... th Metastatic Prostate Cancer.
@en
type
label
Adverse Health Events Followin ...... th Metastatic Prostate Cancer.
@en
prefLabel
Adverse Health Events Followin ...... th Metastatic Prostate Cancer.
@en
P2093
P2860
P1433
P1476
Adverse Health Events Followin ...... th Metastatic Prostate Cancer.
@en
P2093
Cathee Till
Catherine M Tangen
Charles Blanke
Ian M Thompson
Jason D Wright
Joseph M Unger
Maha Hussain
Scott Ramsey
William E Barlow
P2860
P304
P356
10.1001/JAMAONCOL.2015.4655
P577
2015-12-23T00:00:00Z